)
Visual
test
Century Therapeutics
Century Therapeutics (IPSC) investor relations material
Century Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Advanced lead beta islet cell therapy (CNTY-813) for type 1 diabetes, with IND submission expected in Q4 2026 and initial clinical data anticipated in 2H 2027.
Progressed CD19-targeted CAR-iT cell therapy (CNTY-308) toward clinical entry in 2026.
Strengthened balance sheet with $135 million private placement, extending cash runway into Q1 2029.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $117.1 million as of December 31, 2025, down from $220.1 million at year-end 2024.
Collaboration revenue was $109.2 million for 2025, up from $6.6 million in 2024, primarily from a Bristol-Myers Squibb agreement.
R&D expenses decreased to $95.7 million in 2025 from $107.2 million in 2024, mainly due to lower personnel and manufacturing costs.
G&A expenses fell to $24.0 million in 2025 from $33.2 million in 2024, reflecting lower legal fees and gains on lease and contingent liabilities.
Net loss narrowed significantly to $9.6 million in 2025 from $126.6 million in 2024.
Outlook and guidance
Cash position and recent financing expected to support operations into Q1 2029.
IND submission for CNTY-813 planned for Q4 2026, with initial clinical data expected in 2H 2027.
CNTY-308 anticipated to enter the clinic in 2026, pending regulatory clearance.
Updated preliminary clinical data from the CARAMEL IST study expected in 2026.
CNTY-813: Impact of Allo-Evasion 5.0 on immunosuppression
Explain the drivers for 2025 net loss reduction.
CNTY-308: How does it enhance treatment accessibility?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Century Therapeutics
- Pivot to iPSC-derived beta islet therapy for type 1 diabetes, IND in late 2025, data in 2027.IPSC
Leerink Global Healthcare Conference 202610 Mar 2026 - Lead cell therapy programs targeting diabetes and autoimmune diseases advance toward clinical trials.IPSCTD Cowen 46th Annual Health Care Conference4 Mar 2026
- Raised $135M to advance iPSC cell therapies; registration enables resale of 176M shares.IPSCRegistration Filing5 Feb 2026
- iPSC cell therapies show strong safety, efficacy, and promise for autoimmune and oncology.IPSCGuggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026
- Promising clinical and preclinical progress, platform advances, and strong partnerships drive outlook.IPSCPiper Sandler 36th Annual Healthcare Conference11 Jan 2026
- Shelf registration allows flexible capital raising with strong management and indemnification.IPSCRegistration Filing5 Jan 2026
- Registering 7.87M shares for resale post-acquisition; no proceeds to company, Nasdaq: IPSC.IPSCRegistration Filing16 Dec 2025
- Biotech seeks $200M to advance allogeneic iPSC cell therapies for autoimmune diseases and cancer.IPSCRegistration Filing16 Dec 2025
- iPSC-derived cell therapies advance toward clinical trials, enabled by Alloevasion technology.IPSCPiper Sandler 37th Annual Healthcare Conference4 Dec 2025
Next Century Therapeutics earnings date
Q1 202611 May, 2026
Century Therapeutics
Next Century Therapeutics earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage